# A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

> **NCT02543645** · PHASE1 · TERMINATED · sponsor: **Celldex Therapeutics** · enrollment: 18 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Kidney Diseases
- Kidney Neoplasms
- Urogenital Neoplasms
- Urologic Diseases
- Urologic Neoplasms
- Neoplasms by Histologic Type
- Neoplasms
- Clear-cell Metastatic Renal Cell Carcinoma
- Melanoma
- Triple Negative Breast Cancer
- Bladder Cancer
- Head and Neck Cancer
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Combination of Varlilumab and Atezolizumab

## Key facts

- **NCT ID:** NCT02543645
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2017-04
- **Final completion:** 2017-05-22
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Portfolio re-prioritization
- **Last updated:** 2018-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02543645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02543645, "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02543645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*